GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rein Therapeutics Inc (NAS:RNTX) » Definitions » Forward Dividend Yield %

RNTX (Rein Therapeutics) Forward Dividend Yield % : 0.00% (As of Mar. 23, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Rein Therapeutics Forward Dividend Yield %?

As of today (2025-03-23), the Forward Annual Dividend Yield of Rein Therapeutics is 0.00%.

As of today (2025-03-23), the Trailing Annual Dividend Yield of Rein Therapeutics is 0.00%.

RNTX's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.44
* Ranked among companies with meaningful Forward Dividend Yield % only.

Rein Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Rein Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, Rein Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rein Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Forward Dividend Yield % falls into.



Rein Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Rein Therapeutics  (NAS:RNTX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Rein Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Rein Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rein Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
12407 N. Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.
Executives
James Brian Windsor officer: See Remarks 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey director C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso director FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler officer: See Remarks 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros director C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H director C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic officer: SVP, Chief Medical Officer C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory officer: SVP, Chief Business Officer 305 THAYER POND ROAD, WILTON CT 06897
William Mckee director
Nolan Howard Sigal director 941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall officer: VP, Finance and Operations C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd officer: President and CEO 10445 PACIFIC CENTER CT, SAN DIEGO CA 92121